Gyre Therapeutics, Inc. GYRE Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s derivative liabilities (non-current)?
- Gyre Therapeutics, Inc. (GYRE) reported derivative liabilities (non-current) of $2.87M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s derivative liabilities (non-current) changed year-over-year?
- Gyre Therapeutics, Inc.'s derivative liabilities (non-current) decreased by 15.9% year-over-year, from $3.41M to $2.87M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s derivative liabilities (non-current)?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s derivative liabilities (non-current) has grown at a -52.0% compound annual growth rate (CAGR), from $12.84M to $2.96M.
- What does derivative liabilities (non-current) mean?
- This represents the fair value of derivative financial instruments that are classified as liabilities and are not expected to be settled within the current fiscal year. These instruments often arise from complex financing arrangements, hedging activities, or embedded features in debt or equity securities. Monitoring this balance is critical for assessing long-term financial risk and the potential impact of market volatility on the company's balance sheet.